CA2708988C - Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules - Google Patents

Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules Download PDF

Info

Publication number
CA2708988C
CA2708988C CA2708988A CA2708988A CA2708988C CA 2708988 C CA2708988 C CA 2708988C CA 2708988 A CA2708988 A CA 2708988A CA 2708988 A CA2708988 A CA 2708988A CA 2708988 C CA2708988 C CA 2708988C
Authority
CA
Canada
Prior art keywords
compound
formula
composition according
cells
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2708988A
Other languages
English (en)
French (fr)
Other versions
CA2708988A1 (fr
Inventor
Olivier Zelphati
Stephane Moutard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OZ BIOSCIENCES Sas
Original Assignee
OZ BIOSCIENCES Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OZ BIOSCIENCES Sas filed Critical OZ BIOSCIENCES Sas
Publication of CA2708988A1 publication Critical patent/CA2708988A1/fr
Application granted granted Critical
Publication of CA2708988C publication Critical patent/CA2708988C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0291—Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
    • C07C69/58—Esters of straight chain acids with eighteen carbon atoms in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2708988A 2007-12-19 2008-12-16 Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules Active CA2708988C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0708861A FR2925491B1 (fr) 2007-12-19 2007-12-19 Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules
FR0708861 2007-12-19
PCT/FR2008/001755 WO2009106713A2 (fr) 2007-12-19 2008-12-16 Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules

Publications (2)

Publication Number Publication Date
CA2708988A1 CA2708988A1 (fr) 2009-09-03
CA2708988C true CA2708988C (fr) 2017-03-28

Family

ID=39731919

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2708988A Active CA2708988C (fr) 2007-12-19 2008-12-16 Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules

Country Status (6)

Country Link
US (1) US9107931B2 (cg-RX-API-DMAC7.html)
EP (1) EP2285772B1 (cg-RX-API-DMAC7.html)
JP (1) JP2011509074A (cg-RX-API-DMAC7.html)
CA (1) CA2708988C (cg-RX-API-DMAC7.html)
FR (1) FR2925491B1 (cg-RX-API-DMAC7.html)
WO (1) WO2009106713A2 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2766482B1 (en) 2011-10-11 2016-12-07 The Brigham and Women's Hospital, Inc. Micrornas in neurodegenerative disorders
WO2013148219A1 (en) 2012-03-28 2013-10-03 University Of Central Florida Research Foundation, Inc. Anti-metatstatic agents predicated upon polyamine-macrocyclic conjugates
US9346741B2 (en) 2012-03-28 2016-05-24 University Of Central Florida Research Foundation, Inc. Polyamine transport selective therapeutic agents with enhanced stability
US9603799B2 (en) 2013-03-15 2017-03-28 Htd Biosystems Inc. Liposomal vaccine adjuvants and methods of making and using same
US20140271815A1 (en) * 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same
US8853278B1 (en) 2013-05-22 2014-10-07 Curza Global, Llc Compositions comprising a biocidal polyamine
US9439433B2 (en) 2013-05-22 2016-09-13 Curza Global, Llc Compositions and methods comprising a biocidal polyamine
US20160110406A1 (en) * 2014-10-16 2016-04-21 Microsoft Technology Licensing, Llc Validation of data across multiple data stores
US12263229B2 (en) 2014-11-10 2025-04-01 Ethris Gmbh Induction of osteogenesis by delivering BMP encoding RNA
JP6640750B2 (ja) * 2015-01-30 2020-02-05 日油株式会社 カチオン性脂質
WO2017186711A1 (en) 2016-04-25 2017-11-02 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
WO2018071679A1 (en) * 2016-10-13 2018-04-19 Carnot, Llc N-acylethanolamide derivatives and uses thereof
WO2018081817A2 (en) 2016-10-31 2018-05-03 University Of Massachusetts Targeting microrna-101-3p in cancer therapy
JP7041166B2 (ja) 2017-04-05 2022-03-23 カーザ グローバル,リミティド ライアビリティ カンパニー トリアリールポリアミンを含む組成物および方法
ES2974368T3 (es) 2019-02-14 2024-06-27 Ethris Gmbh Análisis del efecto de un polirribonucleótido sobre la ciliogénesis
EP4240396B1 (en) 2020-11-04 2025-01-01 Ethris GmbH Ifn-lambda mrna for treating viral infections
WO2023069590A1 (en) * 2021-10-21 2023-04-27 Board Of Regents Of The University Of Nebraska Refillable tissue engineered scaffolds
WO2024121160A1 (en) 2022-12-05 2024-06-13 Ethris Gmbh Regulator(s) of energy homeostasis-encoding rna molecule(s) with increased translation efficiency
EP4480943A1 (en) 2023-06-22 2024-12-25 Oz Biosciences New class of lipids for delivering active ingredients into cells
IT202300015291A1 (it) 2023-07-20 2025-01-20 Fond Riccardo Terzi E Silvio Albini Sistema di rilascio comprendente nanoparticelle lipidiche o polimeriche comprendenti ormoni tiroidei
WO2025097659A1 (en) * 2023-11-08 2025-05-15 Longuide Biopharma Corporation Lipids and lipid nanoparticle formulations
WO2025209467A1 (en) * 2024-04-01 2025-10-09 Longuide Biopharma Corporation Lipids and lipid nanoparticle formulations

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1351368A (fr) * 1960-12-05 1964-02-07 Merck & Co Inc Composés d'isocyanates organiques et leur procédé de fabrication
CH448122A (de) * 1963-10-14 1967-12-15 Hoffmann La Roche Verfahren zur Herstellung von Estern
JPS6039716B2 (ja) * 1982-02-02 1985-09-07 ライオン株式会社 カチオン性界面活性剤組成物
US4749694A (en) * 1984-04-26 1988-06-07 Merck & Co., Inc. Novel lysine esters used as absorption
EP0243449A1 (en) * 1985-10-18 1987-11-04 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
EP0320976A1 (en) * 1987-12-18 1989-06-21 Ajinomoto Co., Inc. Arginine derivatives and cosmetic compositions comprising the same
AU666416B2 (en) * 1993-01-29 1996-02-08 Tanabe Seiyaku Co., Ltd. Ellipticine derivative and process for preparing the same
GB9326518D0 (en) * 1993-12-29 1994-03-02 Sandoz Ltd Organic compounds
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5719131A (en) * 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US6071890A (en) * 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5939401A (en) * 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
JPH08239398A (ja) * 1995-03-03 1996-09-17 Sogo Yatsukou Kk 水不溶性、自己支持性透明dna・脂質複合体フィルムおよびその製造方法
EP0775751A3 (en) * 1995-11-22 1998-06-10 F. Hoffmann-La Roche Ag Cell transfection
EP0784984B1 (en) * 1996-01-17 2003-07-02 F. Hoffmann-La Roche Ag Transfection competent molecules
ATE244021T1 (de) * 1996-01-17 2003-07-15 Hoffmann La Roche Transfektionskompetente moleküle
EP1046394A3 (en) * 1999-04-19 2001-10-10 ImaRx Pharmaceutical Corp. Novel compositions useful for delivering compounds into a cell
US20050085426A1 (en) * 2000-09-05 2005-04-21 Michel Bessodes Acid-sensitive compounds, preparation and use thereof
GB0106041D0 (en) * 2001-03-12 2001-05-02 Cancer Res Ventures Ltd Lipids and liposomes
AU2002320470A1 (en) * 2001-07-11 2003-01-29 Musc Foundation For Research Development Modulators of ceramidase and methods of use based thereon
JP2005527639A (ja) * 2001-11-02 2005-09-15 インサート セラピューティクス インコーポレイテッド Rna干渉の治療的利用のための方法及び組成物
WO2003082809A1 (en) * 2002-03-27 2003-10-09 Glaxo Group Limited Diaminoacid-aminoacid-polyamine based gemini surfactant compounds
US7838685B2 (en) * 2005-04-27 2010-11-23 Shinji Takeoka Cationic amino acid type lipid
BRPI0620811A2 (pt) * 2005-12-30 2011-11-22 Revance Therapeutics Inc heterÈmeros de arginina para administração tópica

Also Published As

Publication number Publication date
CA2708988A1 (fr) 2009-09-03
FR2925491A1 (fr) 2009-06-26
WO2009106713A2 (fr) 2009-09-03
US20120015865A1 (en) 2012-01-19
WO2009106713A3 (fr) 2009-11-26
EP2285772A2 (fr) 2011-02-23
FR2925491B1 (fr) 2010-09-03
US9107931B2 (en) 2015-08-18
JP2011509074A (ja) 2011-03-24
EP2285772B1 (fr) 2022-07-13

Similar Documents

Publication Publication Date Title
EP2285772B1 (fr) Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules
AU713039B2 (en) Lipids and their use, for example, in liposomes
AU732333B2 (en) Dimeric cationic lipids on dicystine basis
US9265833B2 (en) Lipid dipeptide and gel
JP5441693B2 (ja) 新規脂質ペプチド並びにヒドロゲル
EP4334455A1 (en) Lipid compositions comprising peptide-lipid conjugates
FR2759382A1 (fr) Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
US20170190661A1 (en) Aromatic Ionizable Cationic Lipid
US20210213010A1 (en) Tlr7/8 agonists and liposome compositions
US20220378702A1 (en) Peptide-lipid conjugates
EA006021B1 (ru) Применение липосом для транспорта лекарственных средств или веществ с косметической активностью на основе сложных эфиров l-карнитина и композиции, включающие липосомы
JP5403324B2 (ja) タンパク質又は遺伝子導入用試薬
CN104987360A (zh) 一类双烷氧酰胺烷基阳离子肽脂质及其合成方法和应用
Neuberg et al. Design and evaluation of ionizable peptide amphiphiles for siRNA delivery
US9822083B2 (en) Amphiphilic derivatives of triazamacrocyclic compounds, products and compositions including same, and synthesis methods and uses thereof
US20240336655A1 (en) Amphiphilic peptides for nucleic acid and protein delivery
EP4480943A1 (en) New class of lipids for delivering active ingredients into cells
Cheng et al. Fluorinated amphipathic cationic peptides for intracellular protein delivery and cancer immunotherapy
John Use of an Antibacterial Cell-Penetrating Peptide for Intracellular Protein Delivery and the Identification of Tyrphostin-A9 as an Allosteric Inhibitor of Furin
US20170035886A1 (en) Amphiphilic derivatives of triazamacrocyclic compounds, products and compositions including same, and synthesis methods and uses thereof
FR2777017A1 (fr) Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs applications

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131213

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241211

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260127

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260801